Citigroup Maintains Neutral on Zimmer Biomet Holdings, Raises Price Target to $140
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Joanne Wuensch has maintained a Neutral rating on Zimmer Biomet Holdings (ZBH) and increased the price target from $134 to $140.
April 03, 2024 | 4:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Citigroup has maintained a Neutral rating on Zimmer Biomet Holdings and raised the price target from $134 to $140.
The increase in price target by Citigroup suggests a positive outlook on the stock's value, potentially leading to short-term price appreciation. However, the Neutral rating indicates that the analyst sees the stock as fairly valued at its current price, balancing the potential for both upside and downside.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100